Ionis Pharmaceuticals Inc.
NASDAQ · IONS·Carlsbad, CA·Mid-cap·Approved
Antisense oligonucleotide (ASO) pioneer with multiple approved medicines including Spinraza (partnered) and Wainua (eplontersen) for hereditary ATTR polyneuropathy. Ionis's pipeline spans cardiometabolic (olezarsen, donidalorsen), neurology, and renal diseases using its proprietary RNA-targeted platform.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Ionis Corporate Presentation | Corporate overview | January 1, 2026 | 52 |